Pricing Log in Create free account
Friday 6 November 2026 Export SUPN’s income statement to Excel — free account

Indivior Pharmaceuticals Inc.

SUPN Healthcare Drug Manufacturers Specialty & Generic

Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024.

Revenue
+13.4%
EPS
+241.5%
Free cash flow
+240.7%
Total debt
+51.6%

Quarter to September 2026, against a year earlier

28.21 0.06 +0.21%
Market cap
$5.6B
P/E
7.6×
Fwd P/E
9.5×
Dividend yield
0.00%
F-score
4/9
Altman Z
3.28
Beneish M
−1.52
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.31
Sold, $m 2.83
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — 5 — 3 — — — — 2 — — —
Sell — — — — — — 2 1 — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 5,550.00
Revenue ttm 1,373.00
Net income ttm 450.00
Free cash flow ttm 31.00
Net debt Q 183.00
Valuation
P/E 7.60
Forward P/E 9.51
Price / sales 2.42
Forward P/S Powerpack
Price / FCF 114.79
Price / book 0.00
Financial health
Current ratio Q 0.61 (below 1: weak)
Debt / equity Q (8.13) (negative: negative equity)
Interest coverage Q 90.50
Growth
Revenue growth Q +13.38% (above 0%: growing)
Operating income growth Q +311.36% (above 0%: growing)
EPS, this year +34.55% (at or above 15%: strong)
EPS, next year A +20.78% (at or above 15%: strong)
Revenue, next year A +7.51%
EPS, past 5 yrs —
EPS, next 5 yrs A +22.42% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.9×, against a ten-year median of 2.1×; over the ten years it ranged from −0.6× in 2020 to 3.9× in 2018.
P/E against its own 10 years 21.38%
10-year low 10-year high
P/S against its own 10 years 46.59%
10-year low 10-year high
EV/Sales against its own 10 years 79.49%
10-year low 10-year high
EV/FCF against its own 10 years 94.73%
10-year low 10-year high

Dividends

Yield
0.00%
Annual rate
0.00
Payout ratio
0.00%

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 410 320 195 305
Receivables 254 287 255 286
Inventory 135 167 153 149
Other 467 21 16 40
1,266 827 652 800
2023 2024 2025 Q'26
Payables 204 216 250 181
ST’ Debt 3 18 29 488
Other 40 11 — —
1,290 924 914 1,301

Compound Annual Growth %

10y 5y 3y
Sales 2.02% 13.88% 11.20%
Cash Flow 0.00% 0.00% 0.00%
Earnings (0.82%) 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.93 Actual 1.32

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.65 0.82 Beat by 0.17
Q1 FY26 0.64 0.96 Beat by 0.32
Q2 FY26 0.97 1.15 Beat by 0.18
Q3 FY26 0.93 1.32 Beat by 0.39
Q4 FY26 1.07 — Reports 25 February 2027

EPS $

Mar Jun Sep Dec Year
’26 0.69 0.98 1.12 — —
’25 0.38 0.14 0.33 0.79 1.64
’24 0.45 (0.79) 0.17 0.16 0.05
’23 0.31 0.27 (0.98) (0.55) (0.94)
’22 0.30 0.35 0.28 (1.34) (0.38)
’21 0.50 0.40 0.15 0.25 1.35
’20 (1.10) 0.12 0.06 (0.10) (1.00)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 317 343 356 — —
’25 266 302 314 357 1,239
’24 284 299 307 298 1,188
’23 253 276 271 293 1,093
’22 207 221 232 241 901
’21 180 201 187 223 791
’20 153 150 159 185 647
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (9) 229 97 — —
’25 75 158 (39) (221) (27)
’24 (37) 88 2 (17) 36
’23 (36) (19) 21 (266) (300)
’22 (75) 27 62 (18) (4)
’21 89 71 26 167 353
’20 (146) (2) 26 (71) (193)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (29) 222 83 — —
’25 70 140 (59) (245) (94)
’24 (40) 84 (5) (34) 5
’23 (166) (20) (7) (160) (353)
’22 (74) 25 60 (19) (9)
’21 90 40 44 165 339
’20 (146) (2) 24 (73) (197)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 1,058 1,093 1,005 785 647 791 901 1,093 1,188 1,239 1,373 +1.8% 1,332 1,400 1,489 +6.3%
Gross margin, % 89.89 90.48 87.26 82.17 85.01 83.94 82.35 84.08 80.56 80.15 84.85 (9.7) pt
EBT 98 137 278 180 (173) 190 (95) (149) 20 239 538 +10.4%
EBT margin, % 9.26 12.53 27.66 22.93 (26.74) 24.02 (10.54) (13.63) 1.68 19.29 39.18 +10.0 pt
Net income 149 193 292 178 (156) 213 (85) (129) 7 210 450 +3.9%
Per share, $
Per share, $ Revenue 7.35 7.58 6.91 5.38 4.41 5.43 6.48 7.98 9.00 9.91 11.64 +3.4%
Earnings 0.25 0.40 1.90 0.90 (1.00) 1.40 (0.38) (0.94) 0.05 1.68 3.71 +23.6%
Cash flow 2.83 2.05 2.08 1.03 (1.32) 2.42 (0.03) (2.19) 0.27 (0.22) 0.81 n/m
Capex (0.24) (0.30) (0.03) (0.02) (0.03) (0.10) (0.04) (0.39) (0.23) (0.54) (0.55) +9.2%
Free cash flow 2.58 1.75 2.06 1.01 (1.34) 2.33 (0.06) (2.58) 0.04 (0.75) 0.26 n/m
Book value (2.05) (1.41) 0.45 1.43 0.56 1.39 0.37 (1.39) (2.55) (0.78) (0.51) (10.1%)
Shares, m 144 144 145 146 147 146 139 137 132 125 122 (1.6%)
Valuation, ×
Valuation, × P/E 71.00 68.75 3.55 2.89 0.00 12.32 0.00 0.00 0.00 21.23 7.60 18.0
P/S 2.42 3.63 0.98 0.48 1.66 3.18 3.36 1.94 1.38 3.62 2.42 2.3
P/B 0.00 0.00 14.87 1.82 13.10 12.38 59.28 0.00 0.00 0.00 0.00 10.1
EV/Sales 2.27 3.28 0.30 (0.56) 0.70 2.09 2.63 1.78 1.39 3.72 2.91 1.8
EV/FCF 6.52 15.13 1.00 (3.02) (2.26) 4.90 (237.05) (5.52) 330.75 (48.52) 137.89 6.2
Cash, $m
Cash, $m Operating cash flow 407 295 303 151 (193) 353 (4) (300) 36 (27) 96 n/m
Capex (35) (43) (4) (3) (4) (14) (5) (53) (31) (67) (65) +7.5%
Free cash flow 372 252 299 148 (197) 339 (9) (353) 5 (94) 31 n/m
Balance, $m
Balance, $m Working capital (40) 371 511 618 588 640 240 (24) (97) (262) (501) +23.2%
Net debt (157) (381) (683) (823) (624) (860) (653) (170) 13 124 183 n/m
Shareholders’ equity (295) (203) 66 209 82 203 51 (191) (337) (98) (60) (11.5%)
Returns, %
Returns, % ROA 3.26 4.37 18.39 8.38 (9.30) 12.19 (2.94) (7.31) 0.46 16.69 32.82 +13.4 pt
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 629.81 283.03 +629.8 pt
ROE (12.20) (23.29) (401.46) 97.45 (101.72) 143.86 (41.73) 182.98 (2.65) (96.33) (337.83) (84.1) pt
People
People Employees 965 1,023 915 796 788 885 953 1,164 1,051 838 — (1.6%)
Revenue/emp, $m 1.10 1.07 1.10 0.99 0.82 0.89 0.95 0.94 1.13 1.48 — +3.4%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 2 Nov 2026

Indivior Pharmaceuticals Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
RDY Dr. Reddy's Laboratories Ltd $12.1B 44.4× 30.7× −10.09% (below 0%: shrinking) −36.84% (below 0%: shrinking) −70.49% (below 0%: shrinking) 52.13% 14.63% Compare
ALKS Alkermes plc $7.5B — (loss-making) — (loss-making) +21.80% (above 0%: growing) −80.60% (below 0%: shrinking) +6.78% (above 0%: growing) 80.38% 7.50% Compare
KNSA Kiniksa Pharmaceuticals International, plc $6.9B 62.1× 67.8× +58.12% (above 0%: growing) +142.20% (above 0%: growing) +43.51% (above 0%: growing) 90.29% 18.97% Compare
AMRX AMNEAL PHARMACEUTICALS, INC. $6.8B 36.9× 44.2× +9.96% (above 0%: growing) +267.00% (above 0%: growing) −50.92% (below 0%: shrinking) 38.73% 11.06% Compare
LNTH Lantheus Holdings, Inc. $6.6B 24.3× 21.3× +1.54% (above 0%: growing) −17.07% (below 0%: shrinking) +7.71% (above 0%: growing) 62.43% 8.26% Compare
HIMS Hims & Hers Health, Inc. $5.6B — (loss-making) — (loss-making) +38.25% (above 0%: growing) n/m +5.09% (above 0%: growing) 63.83% (12.90%) Compare
SUPN Indivior Pharmaceuticals Inc. $5.6B 7.6× 9.5× +13.38% (above 0%: growing) +241.47% (above 0%: growing) +240.68% (above 0%: growing) 85.67% 50.84%
LQDA Liquidia Corporation $4.0B 28.5× 22.1× +1,842.73% (above 0%: growing) n/m +270.23% (above 0%: growing) 93.27% 49.81% Compare
AMLX Amylyx Pharmaceuticals, Inc. $3.5B — (loss-making) — (loss-making) −100.61% (below 0%: shrinking) n/m −24.50% (below 0%: shrinking) 100.00% 0.00% Compare
Median of peers $6.7B 36.9× 30.7× +15.88% −17.07% +5.94% 72.11% 9.66%

All 84 Drug Manufacturers Specialty & Generic stocks →

Pay and ownership Proxy statement filed 27 March 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2024 3.85m 1.19m 57.15
2023 4.39m (5.54m) 70.21

Ownership

Directors and executive officers, together less than 1%
BlackRock, Inc. 14.60%
Oaktree Capital Group Holdings LP 5.83%
Fuller & Thaler Asset Management, Inc. 5.23%
Madison Avenue Partners LP 5.15%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Indivior Pharmaceuticals Inc. (SUPN) Latest News

4 Nov

Impact 4 · · Simply Wall St.

3 Nov

Impact 4 · · Simply Wall St.

2 Nov

Impact 4 · · The Motley Fool
Impact 4 · · GlobeNewswire

31 Oct

Impact 3 · · StockStory

30 Oct

Impact 4 · · The Motley Fool transcript
Impact 4 · · Moby
Impact 4 · · Simply Wall St.

29 Oct

Impact 4 · · MarketBeat
Impact 4 · · StockStory
Impact 4 · · GlobeNewswire
Impact 4 · · Zacks
Impact 4 · · GlobeNewswire earnings
Impact 3 · · Zacks

28 Oct

Impact 4 · · PR Newswire

19 Oct

Impact 3 · · GlobeNewswire earnings

21 Aug

Impact 4 ·
Impact 3 ·
Impact 3 ·

11 Aug

Impact 3 ·

4 Aug

Impact 4 ·

3 Aug

Impact 5 ·
Impact 5 ·
Impact 4 ·
Impact 3 · · MarketBeat
Impact 3 ·

31 Jul

Impact 4 ·

29 Jun

Impact 4 ·

25 Jun

Impact 4 · · Investor's Business Daily

15 Jun

Impact 4 ·

SUPN metrics, ten years each

stockrow.com/SUPN · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com